Loading stock data…
$8.93-0.10 (-1.16%)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV Technologies S.A. in the Healthcare sector is trading at $8.93 with a market capitalization of $804M. Wall Street consensus targets $38.33 (7 analysts), implying a +329.4% move over the next 12 months. The stock is currently near its 52-week low of $8.90, remaining 48.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.60M↓ | -$47.90M↓ | -$45.05M↓ | -$34.28M↑ | -$41.20M |
| Net Income | -$50.40M↓ | -$47.60M↓ | -$44.83M↓ | -$33.16M↑ | -$41.90M |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed...